When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CPRX - Mixed Fortunes Make Investing In Catalyst Pharmaceuticals A Little Too Risky
Catalyst Pharmaceuticals Inc.
Investment Thesis
Catalyst Pharmaceuticals (CPRX) has had an eventful year. The company has launched a new drug after 5 years in development, faced criticism for its perceived excessive pricing point, lost its exclusivity after the FDA approved a rival treatment, launched a lawsuit against the FDA in response, and failed a phase 3 clinical trial.
On the positive side, Catalyst has turned into a profitable company, delivered $72m of sales in the first nine months of 2019, and projects sales of $130m for 2020. Q3 EPS was $013.